Table 1.
N (%) | |
---|---|
Demographic Characteristic | (N=35) |
Age, mean years (SD) | 42.5 (±13.8) |
Male | 22 (63%) |
Caucasian | 31 (89%) |
Underlying malignancy | |
AML | 17 (49%) |
MDS | 4 (11%) |
CML | 4 (11%) |
Non-Hodgkin’s Lymphoma | 3 (9%) |
ALL | 2 (6%) |
Othera | 5 (14%) |
CMV serologies (donor / recipient) | |
Positive or negative / positive | 29 (83%) |
Positive / negative | 2 (6%) |
Negative / negative | 4 (11%) |
Allogeneic HSCT | 35 (100%) |
Unrelated donor | 21 (60%) |
HLA Matched | 24 (69%) |
Peripheral Blood HSCT | 19 (54%) |
Conditioning regimen | |
Cyclophosphamide / Single-dose TBI (550cGy) | 23 (65%) |
Busulfan / Cyclophosphamide | 6 (17%) |
Fractionated TBI / Cyclophosphamide | 3 (9%) |
Other | 3 (9%) |
Graft versus host disease | 25 (71%) |
Skin | 23 (66%) |
Gastrointestinal | 11 (31%) |
Hepatic | 5 (14%) |
Steroid use, mean days (SD) | 39 (±20) |
Charlson Comorbidity Index at HSCT, median (range)b | 2.5 (2–5) |
SD – Standard deviation; AML – Acute Myelogenous Leukemia; MDS – Myelodysplastic Syndrome; CML – Chronic Myelogenous Leukemia; ALL – Acute Lymphoblastic Leukemia; CMV – Cytomegalovirus; HSCT – Hematopoietic Stem Cell Transplant; HLA – Human Leukocyte Antigen; TBI – Total Body Irradiation
Other malignancies included aplastic anemia, prolymphocytic leukemia, and Hodgkin’s lymphoma
Age was not scored, as it was evaluated as a separate factor